Significance: ApCAFs derived from myeloid cells promote the progression of HNSCC by increasing the ratio of CD4+/CD8+ cells, indicating potential novel targets to be used to treat the human HNSCC. This evidence concerns the gene CD4 and head and neck squamous cell carcinoma.